证券代码：600671 证券简称：天目药业 公告编号：临 2025-029 杭州天目山药业股份有限公司 关于 2024 年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州天目山药业股份有限公司（以下简称"公司"或"天目药业"）于 2025 年 6 月 5 日 15:00-16:00 在上海证券交易所上证路演中心 （https://roadshow.sseinfo.com/）通过网络互动方式召开 2024 年度业绩说明 会。现就有关事项公告如下： 一、 业绩说明会召开情况 2025 年 5 月 27 日，公司在上海证券交易所网站（www.sse.com.cn）及指定 信息披露媒体披露了《杭州天目山药业股份有限公司关于召开 2024 年度业绩说 明会的公告》。 2025 年 6 月 5 日 15:00-16:00，公司董事长刘加勇先生、总经理孙学建先生、 董事会秘书党国峻先生、财务总监王一惠女士、独立董事盛筱艨女士出席了本次 业绩说明会，与投资者进行沟通与交流，就投资者关注的问题进行了回复。 二、 ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-028 杭州天目山药业股份有限公司 关于全资子公司收到药品再注册批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州天目山药业股份有限公司（以下简称"公司"）获悉，公司下属全资子 公司黄山市天目药业有限公司（以下简称"黄山天目"）于近日收到安徽省药品 监督管理局核准签发的《药品再注册批准通知书》。现将相关情况公告如下： 一、药品再注册批准通知书的主要信息 1、生脉饮 通知书编号：2025R038451 剂型：合剂 申请事项：境内生产药品再注册 规格：每支装 10ml 注册分类：中药 药品注册标准编号：《中国药典》2020 版一部 原药品批准文号：国药准字 Z34020345 包装规格：10ml×10 支/盒 药品有效期：24 个月 审批结论：经审查，同意本品再注册。由于本品长期未生产，恢复生产时， 须向我局提出现场检查申请，经我局现场检查并抽验一批产品合格后，方可上市 销售。 上市许可持有人/生产企业：黄山市天目药业有限公司 药品批准文号：国 ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-027 杭州天目山药业股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 06 月 05 日 （星期四） 15:00-16:00 会议召开地点：上海证券交易所上证路演中心 （网址：https://roadshow.sseinfo.com/） 就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 06 月 05 日（星期四）15:00-16:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 05 月 28 日（星期三）至 06 月 04 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 tianmuyaoye@126.com 进行提问。公司将在说明会上对投资者普遍关注 的问 ...

Group 1 - The stock price of Tianmu Pharmaceutical (600671) closed at 12.35 yuan on May 23, 2025, down 0.64%, with a turnover rate of 4.2% and a trading volume of 51,100 shares, amounting to a transaction value of 64.27 million yuan [1] - As of May 20, 2025, the number of registered shareholders of the company was 9,075 [2] - The company’s subsidiary, Tianmu Mountain Health Technology (Shenzhen) Co., Ltd., has registered several trademarks in the pet and health food industries, indicating a potential entry into these markets [2] - The company is focused on the research, production, and sales of pharmaceuticals, raw materials, and health products, while also engaging in drug circulation and medical technology services [2] Group 2 - The company is monitoring market dynamics and regulatory changes, particularly the newly released "Major Asset Restructuring Management Measures" by the CSRC, and will comply with disclosure obligations if relevant matters arise [2] - The company acknowledged that stock price fluctuations in the secondary market are influenced by macroeconomic conditions, industry status, and market expectations [3] - On May 23, 2025, the net capital flow for Tianmu Pharmaceutical showed a net outflow of 6.177 million yuan from institutional investors and a net inflow of 6.9742 million yuan from retail investors [4][5]

Core Viewpoint - Tianmu Pharmaceutical has experienced a significant turnaround in its financial performance in 2024, primarily due to increased revenue from health products and medical training services, largely supported by local enterprises in Qingdao [2][3][4]. Financial Performance - Tianmu Pharmaceutical's revenue for the first half of 2024 was 0.6 billion, with a net profit of -0.19 billion [3]. - In the second half of 2024, the company's revenue surged to 1.58 billion, accounting for 72.59% of the total annual revenue, with a net profit of 0.34 billion [4]. - The fourth quarter alone contributed 0.93 billion in revenue, representing 42.62% of the annual total [4]. Business Segments - Health products became the largest business segment for Tianmu Pharmaceutical in 2024, generating 0.68 billion in revenue, a 322% increase year-on-year [5]. - Medical training services followed, with revenue of 0.43 billion, marking a 286% increase [5]. Customer Base and Relationships - Eight out of the top ten customers for Tianmu Pharmaceutical's health products in 2024 were Qingdao-based companies, with six being construction-related firms [5]. - The company has been questioned regarding the sustainability of its new customer relationships, particularly with local construction firms linked to its controlling shareholder [5][6]. Acquisitions and Projects - In 2024, Tianmu Pharmaceutical acquired a 51% stake in Qingdao Simulation Medicine, which significantly contributed to its revenue growth [6]. - Qingdao Simulation Medicine won a project from the Qingdao Health Commission worth 39.55 million, enhancing Tianmu's financial performance [6][9]. Future Outlook - The sustainability of the revenue growth from Qingdao Simulation Medicine is under scrutiny, with the company planning to enhance its capabilities and pursue additional contracts for 2025 [10].

Core Viewpoint - Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. (Tianmu Pharmaceutical) has successfully ended its "ST" status after being delisted from risk warnings by the Shanghai Stock Exchange, marking a significant turnaround in its performance following the acquisition by Qingdao Laoshang State-owned Assets [1][3] Company Overview - Tianmu Pharmaceutical, established in 1958 and listed in 1993, has faced numerous challenges over its 30-year history, including governance issues and financial losses, leading to its stock being under risk warnings since June 2020 [2][3] - The company was acquired by Qingdao Huilong Huaze Investment Co., Ltd. in August 2023, which became the new controlling shareholder, providing a much-needed capital infusion of over 1.1 billion yuan for a 29.99% stake [3][4] Financial Performance - Following the acquisition, Tianmu Pharmaceutical's revenue is projected to grow by 78.44% to 217 million yuan in 2024, with a net profit turnaround to 15.25 million yuan [4] - In the first quarter of the current year, the company reported an 88.55% increase in revenue, surpassing 5 million yuan in net profit [4] Strategic Initiatives - The new management has implemented several measures, including waiving 90 million yuan in debt and providing over 100 million yuan in bank credit guarantees, which have positively impacted the company's operations [4] - Tianmu Pharmaceutical is pursuing a dual-center strategy, consolidating its traditional business in Hangzhou while establishing a northern sales center in Qingdao to expand into the Shandong and North China markets [4] Industry Context - The revitalization of Tianmu Pharmaceutical is seen as beneficial for the pharmaceutical and health industry in Laoshang District, which aims to leverage the company's brand to stimulate broader industry growth [5] - The company is actively exploring new avenues in the health industry, transitioning towards a "Chinese medicine + health" model and aiming for an integrated approach in research, production, and sales [5]

Core Viewpoint - Six ST stocks will be delisted from risk warnings and will resume trading on May 20, indicating improved financial conditions and compliance with regulatory requirements [2][4][8]. Group 1: Stocks Resuming Trading - ST Aonong will change its name to Aonong Biological and has received a standard unqualified audit report for its 2024 financials, showing a net asset of 2.566 billion and a net profit of 579 million [4]. - ST Mingjia will change its name to ST Mingjia Hui and continues to face other risk warnings due to negative net profit and low revenue, but has received approval to resume trading [5][6]. - ST Zhongtai, ST Shengda, and ST Muyou will also resume trading with name changes, having rectified previous compliance issues and received standard unqualified audit reports [8]. Group 2: Major Asset Restructuring Announcements - Xunbang Intelligent plans to acquire control of Wuxi Yindi Chip Microelectronics through a combination of share issuance and cash payments, focusing on the automotive chip sector [12]. - Huibo Yuntong intends to purchase 67.91% of Baode Computer Systems, aiming to enhance its competitive edge by integrating software and hardware solutions [13].

Summary of Key Points Core Insights - The report highlights the upcoming listings and trading activities of several companies on May 19, 2025, indicating a busy market day with multiple new entries [1][2][3]. Upcoming Listings - Company 001390 Guqi Fur Material will be available for online subscription on May 19, 2025 [1]. - Companies 301595 N Taili and 603014 N Weigao will officially list on the same day, with allocations for general institutional investors [1]. - Company 920060 Wanyuantong will also list on May 19, 2025, specifically for the public portion [1]. Suspension Announcements - Company 002092 ST Zhongtai and 002259 ST Shengda will be suspended for one day due to the announcement of the withdrawal of other risk warnings [2]. - The Invesco Great Wall S&P Consumer Select ETF (QDII) and Guotai S&P 500 ETF will also be suspended until 10:30 AM on May 19, 2025, to protect investor interests [2]. - Company 300506 *ST Mingjia will be suspended for one day following the announcement of the withdrawal of delisting risk warnings [2]. Special Suspensions - Company 000151 Zhongcheng Co. will be suspended due to plans for issuing shares to acquire assets and raise matching funds, effective from May 16, 2025 [3]. - Company 000584 *ST Gongzhi and 000622 *ST Hengli will also face suspensions due to potential delisting risks and failure to disclose periodic reports within the legal timeframe [3]. - Company 002336 *ST Renle will be suspended for one day due to the announcement of potential delisting risks [3].

Core Viewpoint - ST Muyu Pharmaceutical Co., Ltd. is undergoing a strategic transformation following a change in control, with improved financial performance and operational efficiency expected in the coming years [2][3]. Group 1: Company Overview - ST Muyu is the first A-share listed company in Hangzhou and the first A-share listed company for traditional Chinese medicine preparations in China [2]. - The actual controller of the company has changed to the Qingdao Laoshan District Finance Bureau, which has led to a series of equity acquisitions and management changes [2]. Group 2: Financial Performance - In 2024, the company achieved a net profit attributable to shareholders of 15.25 million yuan, with a net profit of 9.96 million yuan after deducting non-recurring gains and losses [2]. - The company reported a significant increase in revenue for the first quarter of 2025, reaching 52.29 million yuan, representing a year-on-year growth of 88.55% [3]. - The net profit for the first quarter of 2025 was 5.09 million yuan, marking a turnaround from previous losses [3]. Group 3: Management and Strategy - A professional management team with rich industry experience has been established under the new state-owned control, which is expected to enhance decision-making and market positioning [3]. - The company is focusing on core businesses such as traditional Chinese medicine, raw materials, and health products, while also optimizing operational strategies to reduce costs and increase efficiency [3]. - The completion of internal control defect rectification has been confirmed, with a standard unqualified opinion issued by the accounting firm on the internal control audit report [3].

关于撤销风险警示的原因，公司公告指出，2025年4月28日，容诚会计师事务所（特殊普通合伙）对公司2024年 度财务报告出具了标准无保留意见的审计报告。经审计，截至2024年12月31日，公司期末归属于上市公司股东 的净资产为256,618.15万元；2024年度，公司实现营业收入876,267.28万元，实现归属于上市公司股东的净利润 为57,934.50万元。公司股票交易满足可以申请撤销股票交易退市风险警示的条件。 根据公司《董事会关于2023年度审计报告非标意见涉及事项影响已消除的专项说明》，董事会认为，公司2023 年度审计报告非标意见涉及事项的影响已消除。容诚会计师事务所（特殊普通合伙）于2025年4月28日向公司出 具《2023年度审计报告非标意见涉及事项已消除的审核报告》，公司2023年度审计报告中与持续经营相关的重 大不确定性段落涉及事项影响已消除。公司股票交易满足可以申请撤销对公司股票实施其他风险警示的条件。 智通财经5月16日讯，今日，三家ST公司*ST傲农、ST目药、*ST科新相继宣布其股票将被撤销ST标识。至此，今年"摘 帽"上市公司数量已超过20家。 ST目药公告称，公司股票将于20 ...